Overview
Description
Aurinia Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of novel therapies for the treatment of autoimmune diseases. The company's primary function is to advance therapeutic options that improve the lives of individuals suffering from debilitating autoimmune conditions. A standout feature of Aurinia Pharmaceuticals is its specialization in nephrology, which includes its flagship product designed to treat lupus nephritis, a severe manifestation of systemic lupus erythematosus impacting kidney function. Aurinia's research and development efforts concentrate on innovative drug platforms, leveraging scientific advancements to address unmet medical needs in the immune system disorders arena. As a key player in the biotech industry, Aurinia Pharmaceuticals contributes to significant advancements in personalized medicine and targeted therapy. By pushing the boundaries of conventional treatment options, the company plays a crucial role in expanding the horizons of autoimmune disease management within global healthcare markets.
About
CEO
Mr. Peter S. Greenleaf M.B.A.
Employees
300
Address
118 Avenue , 14315
Suite 140
Edmonton, T5L 4S6, AB
Canada
Suite 140
Edmonton, T5L 4S6, AB
Canada
Phone
250 744 2487
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNMS